METHODS OF STUDY SELECTION: Randomized controlled trials comparing magnesium
sulfate with placebo/other treatment in patients at risk of preterm delivery were evaluated for …

OBJECTIVE: To systematically review rates of neurologic outcomes reported in childhood for
the preterm fetus exposed to antenatal magnesium sulfate. DATA SOURCES: We searched …

ContextPrenatal magnesium sulfate may reduce the risk of cerebral palsy or death in very
preterm infants. ObjectiveTo determine the effectiveness of magnesium sulfate given for …

Despite improvements in perinatal care, preterm birth still occurs regularly and the
associated brain injury and adverse neurological outcomes remain a persistent challenge …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …

Antenatal administration of magnesium sulfate is an important part of the neuroprotective
strategy for preterm infants. Strong evidence from five randomized controlled trials and five …

We conducted a systematic review and metaanalysis of randomized controlled trials to
determine whether magnesium sulfate administered to women at risk of preterm delivery …

Background Ordinary meta‐analyses indicate that magnesium sulphate (MgSO4) treatment
in women at imminent risk for preterm delivery decreases the offspring's risk of cerebral …

Background Babies born preterm are at an increased risk of dying in the first weeks of life,
and those who survive have a higher rate of cerebral palsy (CP) compared with babies born …

Background Research suggests that fetal exposure to magnesium sulfate before preterm
birth might reduce the risk of cerebral palsy. Methods In this multicenter, placebo-controlled …